Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifosfamide + interferon alfa-2b
- Development stage
- Unknown
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
This drug is a combination of two agents: ifosfamide, an alkylating small molecule chemotherapeutic agent, and interferon alfa‑2b, a recombinant protein cytokine. Ifosfamide acts by cross-linking DNA strands, leading to inhibition of DNA synthesis and function, resulting in cell death. It is primarily used as an antineoplastic agent for various cancers. Interferon alfa‑2b binds to the type I interferon receptor (interferon alpha/beta receptor), activating intracellular signaling pathways that induce antiviral, antiproliferative, and immunomodulatory effects. The combination has been investigated in clinical trials for metastatic renal cell carcinoma and other cancers; it aims to leverage both direct cytotoxicity (ifosfamide) and immune modulation/antitumor activity (interferon alfa‑2b). This regimen has shown some efficacy but also notable toxicity[1][3][4].
- Brand names
- IfexIntron A
- Other names
- ifosfamidaifosfamidumiphosphamideisofosfamideisophosphamideisosfamideinterferon alpha 2-binterferon alpha 2brIFN-alpha 2brIFN-alpha2brIFN-alpha-2b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)DNA
Beyond the preview
Go deeper on ifosfamide + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifosfamide + interferon alfa-2b.